Results 21 to 30 of about 7,548 (263)

The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): a short‐term cost‐effectiveness analysis in the UK setting [PDF]

, 2018
Aim: To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK.
ADVANCE Collaborative Group, American Diabetes Association Consensus Panel, Anderson, Bagust, Bagust, Billings, Blak, Boye, Chubb, Control Group, Currie, Donnelly, Duckworth, Evans, Forst, Gaede, Gaede, Giugliano, Grandy, Hammer, Holman, Hunt, Hunt, Hunt, Inzucchi, Ismail-Beigi, Johnston, Lee, Matza, McCabe, Meneghini, Mezquita-Raya, National Institute for Health and Care Excellence (NICE), Nauck, Parekh, Peyrot, Peyrot, Ridderstråle, Russell-Jones, Shi, Stettler, The Forum for Injection Technique (FIT), TREND-UK, UK Prospective Diabetes Study (UKPDS) Group, UK Prospective Diabetes Study (UKPDS) Group, Walz, Wang, Wild   +47 more
core   +1 more source

Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources [PDF]

, 2016
Aims: To assess resource utilization associated with severe hypoglycaemia across three insulin regimens in a large phase 3a clinical programme involving people with Type 1 diabetes treated with basal–bolus insulin, people with Type 2 diabetes treated ...
Akram, Brod, Budnitz, Dailey, Davies, Donnelly, Evans, Foos, Frier, Frier, Fulcher, Garber, Geller, Gough, Graveling, Greco, Hammer, Harris, Harris, Heller, Heller, Hirsch, International Conference on Harmonisation, Kaneko, Kristensen, Lammert, Leese, Leiter, Levy, Lipska, Lundkvist, MacLeod, Mathieu, Meneghini, Onishi, Onishi, Philis-Tsimikas, Stratton, The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, UK Hypoglycaemia Study Group, UK Prospective Diabetes Study (UKPDS) Group, Vexiau, Waugh, World Medical Association, Zinman   +44 more
core   +1 more source

DUAL I China:在一项对未服用口服降糖药物的中国2型糖尿病患者进行的随机试验中, IDegLira与其单独成分相比改善了血糖控制

Journal of Diabetes, 2022
Background DUAL I China, one of the DUAL trials, assessed efficacy/safety of insulin degludec/liraglutide (IDegLira) in Chinese adults with type 2 diabetes (T2D) not controlled by oral antidiabetic drugs (OADs).
Weiqing Wang, Bue F. Ross Agner, Bin Luo, Lei Liu, Ming Liu, Yongde Peng, Shen Qu, Karolina Amelia Stachlewska, Guixia Wang, Guoyue Yuan, Qiu Zhang, Guang Ning   +11 more
doaj   +1 more source

Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus [PDF]

, 2013
BACKGROUND: Management of diabetes in elderly subjects is complex and careful management of glucose levels is of particular importance in this population because of an increased risk of diabetes-related complications and hypoglycaemia. OBJECTIVE: The aim
F. Søndergaard, G. Koehler, G. Treiber, H. Haahr, H. Hastrup, J. K. Mader, K. Glettler, M. Urschitz, M. Wolf, S. Deller, S. Korsatko, T. R. Pieber   +11 more
core   +1 more source

Efficacy and safety of ultra-long-acting insulin degludec

Therapeutic Advances in Endocrinology and Metabolism, 2012
All patients with type 1 diabetes and significant numbers of those with type 2 diabetes are treated with insulin. Nonadherence to insulin regimen can impact glycaemic control.
Ammar Wakil, Stephen L. Atkin
doaj   +1 more source

Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial [PDF]

, 2016
We compared changes in blood glucose (BG) and risk of hypoglycaemia during and after exercise in 40 patients with type 1 diabetes (T1D) treated with insulin degludec (IDeg) or insulin glargine (IGlar) in a randomized, open-label, two-period, crossover ...
Richard Bracken, Steve Bain
core   +1 more source

National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment

Сахарный диабет, 2014
In June 2014, the national experts on diabetes mellitus discussed the opportunities to improve the efficacy and outcomes of diabetes treatment using the strategy of patient-oriented care in diabetes.
Gagik Radikovich Galstyan
doaj   +1 more source

In search of the ideal basal insulin: Does the new-generation ultra-long-acting insulin, degludec, provide the answer? [PDF]

, 2013
published_or_final_versio
Hui, YLE, Lam, KSL
core   +1 more source

Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements

Therapeutic Advances in Endocrinology and Metabolism, 2018
Background: We wanted to determine whether basal insulin requirements change when patients transition from insulin glargine U-100 (Gla-100) to insulin glargine U-300 (Gla-300) or insulin degludec.
Scott M. Pearson, Jennifer M. Trujillo
doaj   +1 more source

The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design

BMC Endocrine Disorders, 2019
Background Hypoglycaemia, especially nocturnal, remains the main limiting factor of achieving good glycaemic control in type 1 diabetes. The effect of first generation long-acting insulin analogues in reducing nocturnal hypoglycaemia is well documented ...
Rikke Mette Agesen, Amra Ciric Alibegovic, Henrik Ullits Andersen, Henning Beck-Nielsen, Peter Gustenhoff, Troels Krarup Hansen, Christoffer Hedetoft, Tonny Jensen, Claus Bogh Juhl, Susanne Søgaard Lerche, Kirsten Nørgaard, Hans-Henrik Parving, Lise Tarnow, Birger Thorsteinsson, Ulrik Pedersen-Bjergaard   +14 more
doaj   +1 more source